PTAB upholds 23 claims of Seer's particle proteomics patent in Bruker challenge

Seer, Inc.

PTAB Final Written Decision on March 23, 2026, upholds five challenged and 18 unchallenged claims of U.S. Patent No. 11,435,360.
Patent covers protein enrichment using engineered nano- and microparticles, core to Seer's Proteograph platform.
Petitioners PreOmics GmbH and Biognosys AG (Bruker subsidiaries) failed to show unpatentability of claims 2,3,7,23,24.
Six claims (1,4,6,22,24,25) were found unpatentable; appeal deadline is May 25, 2026.
'360 patent is owned by Brigham and Women's Hospital and exclusively licensed to Seer; CEO vows continued IP defense.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.